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Background
A large number of physiologically relevant proteins com-
prise disulfide bonds: protease inhibitors, proteases,
nucleases, growth factors, venom neurotoxins, and others.
The recombinant expression of these proteins usually rep-
resents an important challenge due to the presence of
disulfide bonds, which may affect protein solubility
inside the cell and lead to misfolding and subsequent
aggregation.
In the last years, specific inhibitors of carboxypeptidases
of the M14A and M14B subfamilies have emerged as
potential drugs able to protect plants against insect attack
and to improve blood clot fibrinolysis [1]. However, the
small size and high number of disulfide bonds present in
these molecules strongly influence their recombinant pro-
duction and further biochemical characterization. Here,
we have tested different systems for the successful expres-
sion of four carboxypeptidase inhibitors from the potato
plant (PCI; 39 residues and 3 S-S), the intestinal parasite
Ascaris suum (ACI; 65 residues and 4 S-S), the medical
leech Hirudo medicinalis (LCI; 66 residues and 4 S-S), and
the soft tick Rhipicephalus bursa (TCI; 75 residues and 6 S-
S)[2].
Results
The recombinant expression of PCI in the methylotrophic
yeast Pichia pastoris, using the pPCI9 vector (Invitrogen),
resulted in a soluble and properly folded protein that was
secreted into the medium to a final yield of 5 mg/liter. The
utilization of the E. coli protease-deficient strain
BL21(DE3) and the vector pBAT4-OmpA [3] routinely
yielded 15 mg/liter of recombinant protein, 10-fold
higher than a previously described E. coli system
(pIN3OmpAIII vector in E. coli strain MC1061) [4]. How-
ever, the scale-up from flask culture to fed-batch fermen-
tor did not improve the previous system (70 versus 200
mg/liter) [5]. Importantly, the PCI expressed in E. coli was
completely folded by addition of redox agents to the cul-
ture supernatant (2 mM Cys-Cys/4 mM Cys, pH 8.5).
Intracellular expression of PCI as a thioredoxin fusion
protein in E. coli ADA494 using the pET-32b vector led to
extremely low yields of soluble protein.
Recombinant LCI was cloned and expressed in periplasm
using E. coli BL21(DE3) cells and the pBAT4-OmpA vec-
tor. Approximately 5 mg/liter of recombinant LCI were
produced in shaker flasks, a moderate improvement com-
pared with the previously reported expression systems in
E.coli using MC1061 and ADA494 cells with the
pIN3OmpAIII and pET-32b vectors, respectively, both
yielding 3 mg/liter [6]. The addition of redox agents also
rendered native folded protein. Recombinant TCI was
expressed in E. coli BL21(DE3) cells using the pBAT4-
OmpA vector, with a yield of 1 mg/liter. Intracellular
expression attempts did not render recombinant TCI. Sim-
ilar to PCI and LCI, the presence of redox agents was nec-
essary to achieve a folded inhibitor. Scale-up studies for
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LCI and TCI were performed in a fed-batch fermentor
using the conditions optimized for PCI. However, low
yields of recombinant protein were obtained for both
molecules (<5 mg/liter).
Currently, we are working on the recombinant expression
of ACI. This protein has been cloned in the pPICZα vector
(Invitrogen) for expression in Pichia pastoris and in the
pBAT4-OmpA and pET-32b vectors for expression in E.
coli. Initial results point out yeast as the most useful sys-
tem for the expression of recombinant ACI. Intracellular
expression systems are also being tested in E. coli.
Conclusion
The use of BL21(DE3) cells and pBAT4-OmpA vector in
combination with redox agents results in soluble and
properly folded protein for all tested inhibitors, indicating
that the periplasmic expression is a good solution to cope
with the problems related to disulfide bond formation.
However, the scale-up of this system does not render high
protein yields. On the other hand, intracellular expression
of these proteins usually leads to misfolding, aggregation
and inclusion bodies formation.
For all proteins, the extracellular expression in the yeast P.
pastoris seems to be an adequate alternative to overcome
the folding problems. Finally, the overall results indicate
that the higher the number of disulfide bonds, the lower
the protein expression yield.
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